NEW YORK (GenomeWeb News) – Investment bank Leerink Swann has raised its valuations on the stocks of Illumina and Life Technologies, citing the benefit of upcoming stimulus funding and expected gains in the next-generation sequencing market.

Analyst Isaac Ro upped his valuation on Illumina's stock to $48-$55 from his previous range of $37-$41. While he slightly lowered his revenue estimate for fiscal-year 2009 to $718.2 million from $718.6 million, he raised his estimate for FY 2010 to $920 million from $896.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28
Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.